HIV Testing Blog

The human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS). HIV can be transmitted through the exchanging of bodily fluids including blood, semen, vaginal discharge, and breast milk. Means of transmission include sexual contact with an infected person, sharing of needles or syringes with an infected person, or through blood transfusions with infected blood. Low quantities of HIV has been found in the saliva and tears of some AIDS patients; however, contact with saliva or tears has never resulted in an HIV transmission.

Healthcare workers are often exposed to the virus at work; however, it is unlikely that they will contract the virus from a patient. Since December 2001, there have been only 57 documented reports of patient-to-worker HIV transmission, mainly due to precautionary guidelines that healthcare workers follow. The main risk of transmission for healthcare workers  is through accidental needle sticks or other injury with a contaminated instrument. However, even here the risk is small. “Researchers estimate that only about 0.0-1% or healthcare workers” contract HIV from an accidental needle stick.

This low statistic can be attributed to post-exposure prophylaxis (PEP), which can be taken immediately after exposure to reduce the risk of transmission. PEP uses antiretroviral therapy (ART) to prevent transmission, but often comes with serious side effects including dizziness, fatigue, nausea, vomiting, diarrhea and more. Current antiretroviral drugs cannot cure HIV infection, nor reduce the risk of transmitting it to someone else, but they can suppress the virus to undetectable levels in some cases. It has been estimated that PEP reduces the infection rate among healthcare workers by 79%.

Post-exposure Prophylaxis should begin immediately after the exposure, seeing as how PEP is most effective when it is initiated within two t0 four hours of exposure. The specific dosage of medication depends on a couple factors including the patient’s overall health, the severity of exposure, the availability of antiretrovirals, and if the patient has any known or possible cross-resistance to any drugs. Treatment normally lasts no less than two weeks and no longer than four. Studies show that almost a quarter of those receiving PEP stop taking the medications early because of side effects. As with all forms of treatment, it is less effective if it ends early.

HIV tests should be performed after any risky sexual behavior, even if PEP was used. Immediately after HIV enters the body antibodies are produced to fight off the infection. While these antibodies cannot completely eliminate the virus, we can use their presence to see if HIV is in the blood. Most people develop detectable antibodies within two to eight weeks; however, it may take longer in some people. Most often, the enzyme immunoassay (EIA) test is used to detect HIV antibodies. If a positive result is returned it is confirmed with a follow-up test before making a diagnosis. Typically the Western blot test is used to confirm a positive HIV result. Other testing options include DNA or RNA tests, which instead of looking for antibodies actually look for genetic material of HIV. These tests can be used for early detection of HIV.

With the combination of healthcare precautions and treatment options such as PEP, we have the ability to decrease the number of patient to worker HIV transmissions drastically.

*For the complete article please refer to http://hivtestingblog.com/original-articles/

Scientists have developed what some are calling a “molecular condom”. The “condom” is actually a gel that, if used correctly, could help prevent women from contracting HIV.

The gel was developed to “enable women to protect themselves against HIV without approval of their partner”. To use it the woman would only need to insert the gel a few hours before sex. The gel flows easily at the vaginal pH, and becomes more solid as the pH increases to that of semen. As the gel turns solid it traps AIDS virus particles, preventing them from infecting vaginal cells.

Due to several factors, women often have difficulty convincing their partners to use protections; however, with this new gel the woman wouldn’t even have to negotiate. It is a form of protection she can use on her own, without her partner’s knowledge.

If all goes as planned, the scientists estimate the gel will be tested in humans within three to five years, and it will be available in the years after that.

*For the complete article please visit http://hivtestingblog.com/original-articles/

Researchers have developed a game for HIV-positive youth, +CLICK, designed to reduce secondary transmission of the virus.

+CLICK was developed by Christine Markham, Ph.D., and Ross Shegog, Ph.D., assistant professors of behavioral sciences. The game’s usability and credibility were assessed by HIV-positive (HIV+) youth at a Texas Children’s Hospital clinic. Results from the study were published in the May issue of AIDS Care

“We wanted to create +CLICK so that we could help educate youth on the importance of making proper, healthy decisions to protect their relationships and themselves as well as help to reduce transmission of the HIV virus,” said Markham, lead investigator of the study.

The game was developed as an adjunct to the youths’ traditional clinic-based self-management education.

Replicating a shopping mall, study participants travel through lessons on abstinence, condoms and contraception, and also watch video clips from experts and peers who are also HIV+. +CLICK is designed to target four behaviors: choosing not to have sex; disclosing HIV status to a potential partner; using condoms correctly and consistently; and using an effective method of birth control along with condoms.

Participants were able to play several of the game’s lessons in approximately 15 minutes during their regularly scheduled clinic visits. “Participants were very receptive and enthusiastic about playing the game,” said Leonard. “They also liked that they were able to ask the clinicians questions about what they learned on the lessons.”

For the complete article, please refer to http://www.sciencedaily.com/releases/2009/06/090623133525.htm

Babies who were born with HIV/AIDS in the 1980s have defied initial expectations. No one expected them to live long.

Since the mid-1990s in developed countries, antiretroviral drugs have largely prevented mothers from transmitting HIV/AIDS to their babies.

Nearly 30 young adults and teenagers who were born with HIV/AIDS meet every week at the Jackson Memorial Hospital in Miami, Florida. “We don’t want to talk about HIV every day,” said Eric Koumbou, 19. “If you talk about HIV and you don’t have it and I do, sometimes it makes me angry or makes me sad.”

For the complete article, please see http://www.cnn.com/2009/HEALTH/06/22/hiv.children.generation/index.html?eref=ib_topstories.

Schistosomiasis is a worm disease that primarily exists within rural Africa. The worms typically infect humans who are swimming or washing in snail-infested waters by leaving the snails and burrowing into the skin. The disease starts as a urinary tract infection, but if left untreated it can lead to genital sores. These sores provide an entrance for HIV during sexual intercourse; therefore, increasing the rates of transmission.

Thankfully there is an easy way to reduce the cases of Schistosomiasis. For only 32 cents a child can be treated with the drug praziquantel, which kills the worms and prevents any further infection. A pilot program was performed in Burkina Faso and it suggested that for $22 million we could treat all 70 million children who are infected, and carrying the plan out for a decade would cost only $112 million.

For a relatively low cost the HIV/AIDS epidemic can be significantly reduced in one of the most affected areas… there is no reason not to do it.

* For the complete article, please visit http://hivtestingblog.com/original-articles/